Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses

Cataract Clinical Trial

Official title:

A Two Arm Prospective, Randomized, Double-Masked Clinical Evaluation of Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01241279
• Other study ID #: 657
• Status: Terminated
• Phase: Phase 4
• First received: November 12, 2010
• Last updated: November 25, 2014
• Start date: October 2010
• Est. completion date: December 2011

Study information

• Verified date: November 2014
• Source: Bausch & Lomb Incorporated
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to demonstrate the correlation of near vision and changes in higher order aberrations following lens extraction and to characterize the defocus curves of Crystalens® AO™ intraocular lens (IOL) versus the monofocal aspheric SofPort® LI61AO IOL in adults.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: December 2011
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Subjects must have clear intraocular media other than cataract.

• Subjects must have a clinically documented diagnosis of age-related bilateral cataracts that are considered amenable to treatment with standard phacoemulsification cataract extraction.

• Subjects must be undergoing primary IOL implantation for the correction of aphakia following central continuous curvilinear anterior capsulorrhexis and phacoemulsification cataract extraction.

• Subjects must require a spherical lens power from 10.00 D to 30.00 D.

• Subjects must be willing and able to return for all scheduled follow-up examinations for each eye from days 1 through 180 following surgery.

• Subjects must have = 1.25 D of preoperative corneal astigmatism.

Exclusion Criteria:

• Subjects with corneal pathology potentially affecting topography.

• Subjects whose fundus cannot be assessed preoperatively.

• Subjects with diagnoses of degenerative visual disorders (eg, macular degeneration, or other retinal disorders) that cause potential acuity losses to a level worse than 20/30 as verified by OCT.

• Subjects with conditions with increased risk of zonular rupture, such as pseudoexfoliation syndrome.

• Subjects who have any active inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis.

• Subjects with uncontrolled glaucoma.

• Subjects with previous retinal detachment.

• Subjects with visually significant diabetic retinopathy (proliferative or non-proliferative) which reduces potential acuity to 20/30 or worse.

• Subjects with rubella, bilateral congenital, traumatic, complicated or polar cataract.

• Subjects with marked microphthalmos or aniridia.

• Subjects who have had previous corneal surgery.

• Subjects with irregular corneal astigmatism.

• Subjects with amblyopia which reduces potential acuity to worse than 20/30.

• Subjects with optic atrophy.

• Subjects with iris neovascularization.

• Subjects with clinically significant retinal pigment epithelium/macular changes which reduces potential acuity to 20/30 or worse.

• Subjects with chronic use of systemic steroids or immunosuppressive medications.

• Subjects lacking intact binocular vision.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cataract

Intervention

Device:
• Crystalens AO
Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
• SoftPort LI61AO
Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.

Locations

Country	Name	City	State
United States	Bausch & Lomb	Irvine	California

Sponsors (1)

Lead Sponsor	Collaborator
Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Amplitude of Accommodation	The measurement of optical change in the power of the eye when viewing from far to near. Accommodation decreases as age increases resulting in an inability to focus on near objects.	Visit 4 (postoperative day 120-180)	No
Secondary	Visual Acuity	Number of correct letters on an early treatment diabetic retinopathy study (ETDRS) chart to measure distance visual acuity and the smallest readable print size on an Minnesota Low-Vision Reading (MNREAD) acuity chart for intermediate and near visual acuity (VA). Visual acuity measured in LogMAR.	All visits through visit 4 (day 160-180)	No